WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial

Core Insights - Merck announced positive results from the Phase 3 HYPERION trial for WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH) [1] Group 1 - The trial evaluated WINREVAIR versus placebo, both in combination with background therapy [1] - The study focused on recently diagnosed adults with PAH classified as WHO Group 1, functional class II or III, at intermediate or high risk of disease progression [1] - WINREVAIR demonstrated a reduction in the risk of clinical worsening in the trial participants [1]